These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 22457236)

  • 1. Overall and cause-specific mortality in GH-deficient adults on GH replacement.
    Gaillard RC; Mattsson AF; Akerblad AC; Bengtsson BÅ; Cara J; Feldt-Rasmussen U; Koltowska-Häggström M; Monson JP; Saller B; Wilton P; Abs R
    Eur J Endocrinol; 2012 Jun; 166(6):1069-77. PubMed ID: 22457236
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Health-related quality of life and IGF-1 in GH-deficient adult patients on GH replacement therapy: analysis of the German KIMS data and the Study of Health in Pomerania.
    Moock J; Albrecht C; Friedrich N; Völzke H; Nauck M; Koltowska-Haggström M; Kohlmann T; Wallaschofski H
    Eur J Endocrinol; 2009 Jan; 160(1):17-24. PubMed ID: 18974232
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum insulin-like growth factor I (IGF-I), IGF-binding proteins 2 and 3, and the risk for development of malignancies in adults with growth hormone (GH) deficiency treated with GH: data from KIMS (Pfizer International Metabolic Database).
    Popovic V; Mattsson AF; Gaillard RC; Wilton P; Koltowska-Häggström M; Ranke MB
    J Clin Endocrinol Metab; 2010 Sep; 95(9):4449-54. PubMed ID: 20610598
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Excess mortality associated with hypopituitarism in adults: a meta-analysis of observational studies.
    Pappachan JM; Raskauskiene D; Kutty VR; Clayton RN
    J Clin Endocrinol Metab; 2015 Apr; 100(4):1405-11. PubMed ID: 25658016
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aspects of growth hormone deficiency and replacement in elderly hypopituitary adults.
    Feldt-Rasmussen U; Wilton P; Jonsson P; ;
    Growth Horm IGF Res; 2004 Jun; 14 Suppl A():S51-8. PubMed ID: 15135778
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Response to GH treatment in adult GH deficiency is predicted by gender, age, and IGF1 SDS but not by stimulated GH-peak.
    Feldt-Rasmussen U; Brabant G; Maiter D; Jonsson B; Toogood A; Koltowska-Haggstrom M; Rasmussen AK; Buchfelder M; Saller B; Biller BM
    Eur J Endocrinol; 2013 May; 168(5):733-43. PubMed ID: 23416951
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Baseline characteristics and response to 2 years of growth hormone (GH) replacement of hypopituitary patients with GH deficiency due to adult-onset craniopharyngioma in comparison with patients with nonfunctioning pituitary adenoma: data from KIMS (Pfizer International Metabolic Database).
    Verhelst J; Kendall-Taylor P; Erfurth EM; Price DA; Geffner M; Koltowska-Häggström M; Jönsson PJ; Wilton P; Abs R
    J Clin Endocrinol Metab; 2005 Aug; 90(8):4636-43. PubMed ID: 15928246
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of long-term growth hormone replacement in adults with growth hormone deficiency following cure of acromegaly: a KIMS analysis.
    Tritos NA; Johannsson G; Korbonits M; Miller KK; Feldt-Rasmussen U; Yuen KC; King D; Mattsson AF; Jonsson PJ; Koltowska-Haggstrom M; Klibanski A; Biller BM
    J Clin Endocrinol Metab; 2014 Jun; 99(6):2018-29. PubMed ID: 24694339
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The benefit of long-term growth hormone (GH) replacement therapy in hypopituitary adults with GH deficiency: results of the German KIMS database.
    Spielhagen C; Schwahn C; Möller K; Friedrich N; Kohlmann T; Moock J; Kołtowska-Häggström M; Nauck M; Buchfelder M; Wallaschofski H
    Growth Horm IGF Res; 2011 Feb; 21(1):1-10. PubMed ID: 21093334
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Isolated growth hormone (GH) deficiency in adult patients: baseline clinical characteristics and responses to GH replacement in comparison with hypopituitary patients. A sub-analysis of the KIMS database.
    Abs R; Mattsson AF; Bengtsson BA; Feldt-Rasmussen U; Góth MI; Koltowska-Häggström M; Monson JP; Verhelst J; Wilton P;
    Growth Horm IGF Res; 2005 Oct; 15(5):349-59. PubMed ID: 16168692
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Determinants of cardiovascular risk in 2589 hypopituitary GH-deficient adults - a KIMS database analysis.
    Abs R; Feldt-Rasmussen U; Mattsson AF; Monson JP; Bengtsson BA; Góth MI; Wilton P; Koltowska-Häggström M
    Eur J Endocrinol; 2006 Jul; 155(1):79-90. PubMed ID: 16793953
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GH replacement in 1034 growth hormone deficient hypopituitary adults: demographic and clinical characteristics, dosing and safety.
    Abs R; Bengtsson BA; Hernberg-Stâhl E; Monson JP; Tauber JP; Wilton P; Wüster C
    Clin Endocrinol (Oxf); 1999 Jun; 50(6):703-13. PubMed ID: 10468941
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimizing growth hormone replacement therapy by dose titration in hypopituitary adults.
    Drake WM; Coyte D; Camacho-Hübner C; Jivanji NM; Kaltsas G; Wood DF; Trainer PJ; Grossman AB; Besser GM; Monson JP
    J Clin Endocrinol Metab; 1998 Nov; 83(11):3913-9. PubMed ID: 9814468
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Baseline characteristics and response to GH replacement of hypopituitary patients previously irradiated for pituitary adenoma or craniopharyngioma: data from the Pfizer International Metabolic Database.
    Maiter D; Abs R; Johannsson G; Scanlon M; Jönsson PJ; Wilton P; Koltowska-Häggström M
    Eur J Endocrinol; 2006 Aug; 155(2):253-60. PubMed ID: 16868138
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Three-years of growth hormone (GH) replacement therapy in GH-deficient adults: effects on quality of life, patient-reported outcomes and healthcare consumption.
    Svensson J; Mattsson A; Rosén T; Wirén L; Johannsson G; Bengtsson BA; Koltowska Häggström M;
    Growth Horm IGF Res; 2004 Jun; 14(3):207-15. PubMed ID: 15125882
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sheehan's syndrome: baseline characteristics and effect of 2 years of growth hormone replacement therapy in 91 patients in KIMS - Pfizer International Metabolic Database.
    Kelestimur F; Jonsson P; Molvalilar S; Gomez JM; Auernhammer CJ; Colak R; Koltowska-Häggström M; Goth MI
    Eur J Endocrinol; 2005 Apr; 152(4):581-7. PubMed ID: 15817914
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discontinuation of estrogen replacement therapy in GH-treated hypopituitary women alters androgen status and IGF-I.
    Christiansen JJ; Fisker S; Gravholt CH; Bennett P; Svenstrup B; Andersen M; Feldt-Rasmussen U; Christiansen JS; Jørgensen JO
    Eur J Endocrinol; 2005 May; 152(5):719-26. PubMed ID: 15879357
    [TBL] [Abstract][Full Text] [Related]  

  • 18. From isolated GH deficiency to multiple pituitary hormone deficiency: an evolving continuum - a KIMS analysis.
    Klose M; Jonsson B; Abs R; Popovic V; Koltowska-Häggström M; Saller B; Feldt-Rasmussen U; Kourides I
    Eur J Endocrinol; 2009 Nov; 161 Suppl 1():S75-83. PubMed ID: 19684053
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence and characteristics of the metabolic syndrome in 2479 hypopituitary patients with adult-onset GH deficiency before GH replacement: a KIMS analysis.
    Verhelst J; Mattsson AF; Luger A; Thunander M; Góth MI; Koltowska-Häggström M; Abs R
    Eur J Endocrinol; 2011 Dec; 165(6):881-9. PubMed ID: 21969523
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The value of IGF1 estimation in adults with GH deficiency.
    Mukherjee A; Shalet SM
    Eur J Endocrinol; 2009 Nov; 161 Suppl 1():S33-9. PubMed ID: 19684059
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.